An interventional study of Autologous Probiotics in Rectal Cancer, Gut Microbiomes and Autologous Probiotic Transplantation, sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Peking University Cancer Hospital & Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute — 9 open to participants now, 10 under way, 2 of them phase 3. Rectal Neoplasms · Peking University Cancer Hospital & Institute.
Among the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 with no phase, and was the 12th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →9 of the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute are open now, in 1 country. Recruiting first, the newest first:
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–85
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute
Ages 18–75
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 2
First in 2016; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 81 across the 13 interventional studies, 68 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University Cancer Hospital & Institute is the lead sponsor of 269 studies on the registry; 128 are open to participants now.
3 of the studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229041Phase 3Peking University Cancer Hospital & InstituteTotal Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | 2027-10-01 |
| NCT07366047Peking University Cancer Hospital & InstituteAutologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer | 2027-06-30 |
| NCT07833319Peking University Cancer Hospital & InstituteLocal Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rectal cancer patients who received low anterior resection combined with ileostomy may effectively reduce the probability of anastomotic leakage after surgery. However, due to the long-term semi-abandoned state of the distal colon, the probability of bowel dysfunction after ileostomy closure is very high. The incidence of low anterior resection syndrome (LARS) exceeds 70%, which is twice that of those who did not receive a preventive stoma. The main reasons include postoperative anatomical structure alteration, nerve damage, pathological changes of the colorectal mucosa, and gut microbiota variation, etc. The application of probiotics can significantly improve the bowel function of these patients. In this study, in order to enhance the colonization effect of probiotics, autologous probiotics will be applied to treat patients with defunctioning ileostomy. The primary outcome is the occurrence of major LARS after 6 months of the treatment.
The number of new cases and deaths of colorectal cancer in China is increasing year by year, seriously threatening the lives and health of the Chinese people. The incidence of rectal cancer accounts for 70% of colorectal cancer. Among them, patients with low rectal cancer involve the issue of preserving the anal sphincter. In recent years, with the improvement of chemoradiotherapy, the organ preservation rate has gradually increased. However, patients with advanced rectal cancer who receive neoadjuvant chemoradiotherapy usually need to undergo an ileostomy to decrease the rate of leakage. After ileostomy closure, patients may experience various adverse reactions such as intestinal obstruction, diarrhea, and constipation. The incidence of low anterior resection syndrome (LARS) exceeds 70%. Normally, the distal colon of patients with an ileostomy is in a semi-abandoned state for a long time. The composition of gut microbiota is significantly different, which is an important factor in leading to LARS. Therefore, the regulation of gut microbiota plays an important role in the recovery of bowel function in these patients.
The human body is a complex symbiotic life form composed of its own cells and a large number of symbiotic microbial cells. The number of microorganisms in the human gastrointestinal tract is ten times the number of human cells; the number of genes contained in microorganisms exceeds 10 million, which is 150 times the number of human genes. Gut bacteria have multiple functions, such as food fermentation, protecting the human body from pathogens, stimulating immune responses, and producing vitamins. At the same time, gut microbiota is involved in many kinds of bowel disease. The regulation of gut microbiota composition in the gut is a useful therapeutic strategy for bowel disease. Fecal microbiota transplantation (FMT) is defined as transplanting the functional microbiota from the feces of a healthy person into the gastrointestinal tract of a patient to restore the patient's normal intestinal microbiota and thereby improve intestinal function and overall health. It is divided into autologous fecal microbiota transplantation (aFMT) and heterologous fecal microbiota transplantation (hFMT). Normally, aFMT can improve the restoration of gut microbiota compared with the method of hFMT. Some kinds of disease should be treated by restoring the gut microbiota environment with autologous probiotics to enhance immunity and prevent the possibility of disease occurrence.
This study is a single-arm, single-center clinical trial, and it plans to include 40 rectal cancer patients with ileostomy. Patients with an ileostomy received autologous probiotics (lactobacillus and bifidobacterium) after the ileostomy closure. All patients will take a 100-day supply of high-activity autologous probiotic enteric-coated capsules (100 lactobacillus and 100 bifidobacterium enteric-coated capsules, 1 capsule per day, with each capsule containing a Colony-Forming Units (CFU) activity of no less than 100 billion). The primary outcome is the occurrence of major LARS after 6 months of the treatment. The secondary outcome measures, including quality of life impairment, LARS score, bowel function impairment, fecal continence impairment, were detected after ileostomy closure (1, 3, 6, 12 months). in order to provide new ideas for the treatment of LARS, the aim of this study is to observe the safety and efficacy of autologous probiotics in patients with ileostomy closure and to investigate improvement on LARS in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: 18-80years old; Curative low anterior resection for rectal cancer with defunctioning ileostomy; ileostomy closure within 3-6 month; Preoperative chemoradiotherapy ; No evidence of anastomotic leakage or severe stenosis
Exclusion Criteria:
Tumor recurrence or distant ; Secondary operation with stoma; Prior disease impairing bowel function except for rectal cancer; Any for transanal irrigation; Pregnant or nursing; Serious cardiovascular disease, uncontrolled infections, or other serious uncontrolled concomitant disease; Cognitive or psychological disorder;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with defunctioning ileostomy following low anterior resection for rectal cancer, receive autologous probiotic (lactobacillus and bifidobacterium) after ileostomy closure.
Dietary Supplement: Autologous Probiotics
Patients with defunctioning ileostomy following low anterior resection for rectal cancer, receive autologous probiotics (lactobacillus and bifidobacterium) after ileostomy closure. All patients will take a 100-day supply of high-activity autologous probiotic enteric-coated capsules (100 lactobacillus and 100 bifidobacterium enteric-coated capsules, 1 capsule per day, with each capsule containing a CFU activity of no less than 100 billion)
Number of participants with major low anterior resection syndrome score (LARS score)
Time frame: at the time of 6 months since the start of treatment
Quality of life impairment assessed by Short Form 36 (SF-36)
Quality of life will be assessed by Short Form 36 (SF-36) health questionnaire.
Time frame: at the time of 1, 3, 6, 12 months since the start of treatment
Number of participants with major low anterior resection syndrome score (LARS score)
Time frame: at the time of1, 3, 6, 12months since the start of treatment
Bowel function impairment
Bowel function will be assessed by Memorial Sloan Kettering Cancer Centre Bowel Function Instrument (MSKCC BFI). Stool frequency will be recorded in the day and night.
Time frame: at the time of 1, 3, 6, 12 months since the start of treatment
Fecal continence impairment
Fecal incontinence will be assessed by Wexner incontinence scale (WIS).
Time frame: at the time of 6, 12 months since the start of treatment
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Jun 2027, 17 months later.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 17 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Cancer Hospital & Institute →